Abiopharma

🔍 Van Den Born Simon (Executive)

Company: Marex Group Ltd (MRX)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Acquired 33,582 shares of Ordinary Shares (Direct)
  Date: 2026-08-19 | Code: A | equity_swap_involved: false | shares_owned_after: 1,498,834.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: On September 6, 2023, the Reporting Person was granted an award under the Issuer's 2022 Annual Long Term Incentive Plan (the "Plan"), which vests in the form of ordinary shares subject to (i) performance conditions, including a minimum return on equity underpin and growth in adjusted operating profit before tax, and (ii) continued service through the third anniversary of the grant date, in each case subject to the terms of the Plan. On August 19, 2026, the Remuneration Committee of the Issuer's Board of Directors determined that the performance conditions had been met. The award remains subject to time-based vesting and will fully vest on September 6, 2026.
• F2: The number of ordinary shares reported herein includes (i) 33,582 shares vesting under the Issuer's 2022 Annual Long Term Incentive Plan as described in footnote 1, and (ii) 272,659 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.